Reach out to us

Reach out to us

Graftys is a European innovation driven MedTech company based in France and Belgium.

At Graftys, we develop, manufacture, and commercialize synthetic bone graft substitute, which have very similar chemical composition with natural bone, making it ideal for bone healing and reconstruction.

+30 countries

Graftys’ products are registered in more than 30 countries worldwide.

+80.000 implants

More than 80,000 units of injectable implanted since their launch.

+100 publications

More than 100 scientific papers about Graftys’s products and technologies have been publsihed on different prominent orthopedic journals and newspapers.

What we pursue

Graftys is devoted to bringing safe, efficient, innovative, and ergonomic bone void fillers for patients, orthopedic surgeons, and hospitals, addressing the unmet need for those who suffer from bone diseases and traumatic injury, improving the quality of patients’ life.

Our mission and values

Here at Graftys, we find that our company values are highly important to us. We have established our team according to preselected competences which fit our company’s DNA. We believe our company’s culture has an influence on productivity, creativity and overall profitability.


Patient Centric

Go above and beyond

Extremely passionate

Quality focused


Why choose us?

Our certifications

Manufacturing and quality management system


  • Re-certifications injectables (HBS) & ancillaries (Europe) – granted May 2020

  • FDA (U.S.A) – 510K  – granted July. 2023

  • Re-registration Brazil (ANVISA) – granted Nov. 2018

Management team

Aurélien Valet

CEO & Founder

As Chief Executive Officer and member of executive board, Aurélien brings fifteen years of cross-functional leadership experience in Orthobiologics industry. Prior to joining Graftys in Nov 2021, he served as CEO & President of Biologics 4 life, leading the company’s acquisition and integration by Graftys. Before his time at bio4life, he served as CEO of Graftys where he was responsible for overseeing the development and commercialization of their innovative injectable bone grafts, successfully achieving several regulatory approvals (510k, CE, ANVISA…) and driving the companys’ peak revenue growth until Graftys’ acquisition end of 2017. He holds a, executive MBA from Kedge Business School.

Xavier Ferry


As Chief Financial Officer and member of executive board director of Graftys, Xavier is responsible for the group’s global finances, investor relations and controllership. He joined the Graftys team in Nov 2021 after spending 2.5 years as CFO at Biologics 4 life, where he played a major role in the M&A operation with Graftys. Xavier brings fifteen years of experience as CFO and a seasoned investor in Medtech startups (in which he successfully sold 20 companies). He holds a phD in Pharmacology and a Master of Science in Management.

Scientific collaborations

Awards & supports

Interested in our company?

Leave us a note and we will get back to you as soon as possible.